01Source
What is collected?
Autologous blood is drawn and processed to obtain a plasma fraction intended to contain more platelets than baseline.
PRP · Clinical Hair Treatment · Istanbul
PRP · Clinical Hair Treatment · Istanbul
PRP: Autologous Platelet-Rich Plasma
PRP is prepared from the patient's own blood, but it is not one standard product. The tube, anticoagulant, separation method, cellular content, final volume and intended scalp target all shape what is actually administered.
PRP is not PRF, a stem-cell product or a hair transplant. An online pre-assessment can organise questions, but diagnosis, blood-related factors and suitability require an in-person medical review.
Quick Orientation
Four questions before PRP
The initials alone do not identify the treatment product.
A defensible discussion links the blood source, the full preparation route, the clinical indication and the outcome that will be reviewed.
02Process
How is it prepared?
Tube type, anticoagulant, spin steps, selected layer and final volume are recorded together.
03Indication
What is the target?
Pattern hair loss is separated from inflammatory, scarring, sudden or otherwise unexplained loss.
04Follow-up
What will be measured?
Comparable photographs and, where appropriate, hair counts or shaft measurements define the review point.
What PRP Means
Autologous blood product · variable composition
PRP names a plasma fraction, not a guaranteed biological dose.
Platelet-rich plasma generally refers to plasma prepared with an intended platelet enrichment. The final concentration and other cellular components remain protocol-dependent.
What it may support
- Provide a locally administered autologous adjunct for a defined hair indication
- Keep collection, preparation and administration traceable
- Link one protocol to one documented scalp target
- Allow tolerability and the agreed hair endpoint to be reviewed separately
What it cannot establish
- Diagnose the cause of hair loss from the treatment name
- Create new follicles or restore an absent donor reserve
- Be treated as interchangeable with PRF or another blood product
- Guarantee density, growth, duration or a fixed number of sessions
Evidence for one PRP preparation, population and endpoint cannot automatically be transferred to another protocol or another cause of hair loss.
Medical Suitability
Diagnosis before blood collection
Five decisions determine whether PRP is reasonable to consider.
The assessment separates the hair diagnosis, scalp condition, blood-related factors, alternatives and the planned method of follow-up.
- 01
Clarify the pattern
Onset, pace, family history, previous treatment and signs of active or scarring disease are reviewed.
- 02
Examine hair and scalp
Miniaturisation, inflammation, infection, scarring and the proposed target zone are assessed in person.
- 03
Review blood-related factors
Relevant blood results, bleeding history, medicines and factors affecting platelets or healing are considered.
- 04
Set clinical priority
Treatment of an underlying cause, licensed medicine, observation or surgical assessment may take precedence.
- 05
Record a baseline
The target area, image standard, endpoint and reasons to continue, change or stop are agreed before treatment.
Preparation and Administration
Collection · separation · scalp delivery
PRP becomes reviewable only through a documented chain.
Small changes during collection and processing can alter the product, so the preparation and injection stages are treated as one traceable procedure.
01Collection
Identify the starting sample
Blood is collected for the individual using a system suitable for the intended preparation.
- Record identity and collection time
- Name the tube and anticoagulant
- Review relevant clinical information
02Separation
Describe the plasma fraction
The complete centrifugation route, selected layer, cellular content and usable volume are documented.
- Record every spin step
- Account for platelets and other cells
- Identify the final preparation
03Administration
Match technique to the scalp target
Distribution, depth, asepsis, comfort measures and aftercare follow the confirmed indication.
- Define the treatment zone
- Document route and distribution
- Record the immediate response
A higher platelet count is not automatically a better clinical product. The relevant question is whether a reproducible preparation suits the diagnosis and target tissue.
Evidence and Limits
Promising signals · substantial heterogeneity
PRP evidence is strongest for a narrow diagnostic context, not hair loss in general.
Randomised studies in androgenetic alopecia report mixed but sometimes favourable changes. Small samples, varied products and inconsistent endpoints limit certainty and direct comparison.
Keep the diagnosis narrow
Results in androgenetic alopecia do not establish benefit for autoimmune, scarring or unexplained hair loss.
Keep products separate
Platelet concentration, white-cell content, activation, volume and administration schedules vary between trials.
Read endpoints precisely
Hair count, density, shaft diameter, photography and patient perception are related but not interchangeable.
Retain long-term uncertainty
Optimal repetition, durability and comparative value against established options remain unsettled.
PRP is not given automatic priority over diagnosis-led medical treatment, observation, scalp care, surgery or no intervention.
Individual Treatment Plan
No automatic package
A PRP plan needs a purpose, a review point and a stopping rule.
The number and spacing of possible applications are not inferred from the initials PRP. They depend on indication, product, tolerability and documented change.
Define the baseline
Record diagnosis, medicines, target zone, photographs and the protocol that would be used.
Limit the first phase
Give any initial phase one clear clinical task and a scheduled assessment.
Review the right endpoint
Evaluate safety, scalp findings and the chosen hair measure on their own timescales.
Decide again
Continue, combine, pause or stop only after the agreed review rather than by default.
Course and Follow-Up
Injection response · hair-cycle review
Early scalp reactions are not evidence of later hair change.
Short-term tolerability and a possible hair endpoint are assessed separately, using timeframes that match tissue healing and the hair cycle.
- 01Early
Hours to days
Tenderness, redness, swelling, pinpoint bleeding or bruising may occur after collection and injection.
- 02Healing
Days to weeks
The scalp is reviewed for persistent or unexpected local change rather than judged for hair outcome.
- 03Hair endpoint
Following months
Comparable images and any agreed measurements are repeated after an appropriate interval.
- 04Decision
At the review point
Tolerability, objective findings, effort and alternatives inform the next decision.
Risks and Alternatives
Autologous does not mean risk-free
Collection, processing and injection each carry medical considerations.
Consent covers expected local reactions, less common complications, individual blood-related factors and the option not to proceed.
01Procedure
Collection and injection
Pain, bleeding, bruising, swelling, infection and persistent local symptoms are possible.
02Patient
Personal factors
Blood findings, medicines, active illness, allergy and healing factors can change timing or suitability.
03Alternative
Other pathways
Diagnostic review, established medicine, scalp treatment, observation or surgery may be more appropriate.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Increasing or unexpected symptoms after a procedure require timely in-person medical assessment; website information cannot replace that examination.
Istanbul and Follow-Up
Assessment and return care in one plan
A brief injection appointment is not the whole treatment pathway.
For international patients, the personal examination, any procedure, aftercare information and later review are planned together.
01Before travel
Organise the question
Existing records and treatment history can help identify what needs personal assessment.
02Bağdat Caddesi
Confirm the indication
Hair, scalp, blood-related factors, alternatives and the proposed protocol are reviewed in Istanbul.
03Treatment day
Document the process
If suitable, collection, preparation, administration and the immediate response are recorded.
04After return
Keep follow-up comparable
Aftercare, warning signs, review timing and access to local assessment are agreed before return.
The Doctor Aslan Approach
Product transparency · measurable purpose
PRP is explained through the actual preparation and the actual clinical endpoint.
The method name does not replace a diagnosis. Dr İsmail Aslan reviews the scalp question, the preparation route, realistic alternatives and how a decision will be reassessed.
Diagnosis before method
Hair loss and scalp findings are assessed before PRP enters the discussion.
Make the product visible
Collection, separation, cellular content and final volume remain traceable.
Measure the intended target
Hair endpoints are not borrowed from studies of another tissue or another product.
Agree when to stop
Continuation requires a new balance of findings, burden, uncertainty and alternatives.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about PRP; no personal diagnosis or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is PRP?+
PRP is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for PRP?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Clarify the diagnosis · identify the product